FDA Findings: Backdated and Pre-Signed Records

Contemporaneous is the ALCOA letter people underestimate. A value written down later — from memory, from a sticky note, or “tidied up” before the inspector arrives — may be right, but nobody can prove it. Three Warning Letters show the range: from scraps of paper to outright backdating.

Background: data integrity and ALCOA+ in practice.

What FDA found

Company X1 — pre-signed, backdated, personal diaries

A contract testing laboratory. Under 21 CFR 211.160(a), the letter describes five blank preventive maintenance forms already pre-signed and dated in the “Performed by” section, and a laboratory manager observed during the inspection “signing and backdating spectrometry analysis reconciliation records” to a date months earlier. FDA calls non-contemporaneous recording a repeat observation from prior inspections. Under 21 CFR 211.22, staff recorded procedures, results and method changes in personal diaries, with no procedure controlling them.

FDA found the planned third-party review of backdating inadequate because it did not assess the wider documentation system, identify root causes or address the firm’s data integrity culture.

Company X2 — sticky notes and missing dates

Cited under 21 CFR 211.194(a). According to the letter, volumetric flasks of release and stability samples had no documented preparation date; the analyst said they were prepared days after the last notebook entry; sample weights were on an adhesive note and no standard weight was recorded. FDA restates the expectation that data must be “recorded in a controlled document at the time they are observed or measured.”

Company X3 — pencil first, ink later

Cited under 21 CFR 211.22. The letter describes logbooks with unnumbered pages and no reconciliation, in which volume entries were first written in pencil and later overwritten in ink — so the original entry was not contemporaneously documented. The same letter describes destroyed records and missing raw data (see discarded and shredded original records).

Why this happens

Interpretation — the letters state findings, not root causes. These are common patterns, not claims about these firms.

• The form isn’t where the work is. If the official record is in the office and the work is at the bench, people write on whatever is at hand and transcribe later.
• Pre-signing to save time. Signing a stack of forms in advance feels efficient — and turns the signature into a statement about something that has not happened yet.
• Fixing the record before the audit. Gaps found during preparation for an inspection get “filled” rather than reported as deviations.
• No control over the paper itself. Unnumbered pages and uncontrolled forms make it impossible to tell whether a page was added, removed or rewritten.

What good looks like

Example: a fictional QC lab using controlled worksheets and an electronic lab notebook we’ll call BenchLog.

1. Record at the point of work. The controlled record — worksheet, logbook or electronic entry — is where the activity happens. Balances and instruments print or transfer data directly to it where possible.
2. No scraps, ever. The procedure states that data is never written on loose paper, sticky notes or personal notebooks. FDA’s guidance (question 12) says recording data on paper that will be discarded is not acceptable.
3. Sign only what you did, when you did it. Signatures and dates are applied at the time of the activity. Pre-signed or pre-dated forms are treated as a data integrity deviation.
4. Late entries are allowed — and labelled. If something truly must be recorded later, it is entered as a late entry with the actual date of entry, the date of the activity and a reason. Never backdated.
5. Controlled paper. Forms are issued by QA or document control, numbered and reconciled; logbooks have numbered pages; permanent ink only, corrections by single line with initials, date and reason. FDA’s guidance (question 6) expects blank forms to be controlled by the quality unit or another document control method.
6. Prefer systems that timestamp for you. Where risk justifies it, move high-impact records to validated electronic systems that apply the date and time automatically and keep an audit trail.

Perspective: what FDA’s requests tell you

In X1, FDA explicitly rejected a fix aimed only at the backdating incidents and asked about culture and the whole documentation system. That is the pattern to expect: a non-contemporaneous record is treated as a symptom. The questions that follow are who else does this, how long it has been going on, and why the quality system did not detect it. Training alone rarely answers them; monitoring does — for example, comparing record dates with system logs, access logs or sample timestamps during routine review.

Regulatory basis

• 21 CFR 211.160(a) — laboratory control requirements must be followed and documented at the time of performance.
• 21 CFR 211.194(a) — laboratory records must include complete data from all tests.
• 21 CFR 211.22 — responsibilities of the quality control unit, including written procedures that are followed.
• FDA guidance: Data Integrity and Compliance With Drug CGMP — Questions and Answers (December 2018), question 6 (blank forms) and question 12 (when electronic data becomes a CGMP record, including recording on paper to be discarded). Guidance is non-binding; the regulations are.

EU angle

Check current versions on EudraLex before relying on specific clauses. In EU GMP, contemporaneous recording sits mainly in EudraLex Volume 4, Part I, Chapter 4 (Documentation). A revised Chapter 4 was published as a draft for consultation in July 2025, alongside the Annex 11 revision.

Takeaways

• Written later = not contemporaneous, even if the value is right.
• A pre-signed form is a false statement waiting to happen.
• Late entries are fine; backdated entries are not.
• Control the paper: numbered pages, issued forms, reconciliation.